Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HPV E6 TCR T cells - TCRCure Biotech

Next Previous
Drug Profile

HPV E6 TCR T cells - TCRCure Biotech

Alternative Names: HPV E6-specific TCR-T cells - TCRCure Biotech

Latest Information Update: 30 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TCRCure Biopharma
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Squamous cell cancer
  • No development reported Cervical cancer

Most Recent Events

  • 23 Oct 2024 Xinqiao Hospital of Chongqing reinitiates phase-I/II trial in Squamous cell cancer (Recurrent, Metastatic disease) in China (Parenteral) (NCT04139057)
  • 02 Oct 2024 Xinqiao Hospital of Chongqing suspends a phase-I/II trial in Squamous cell cancer (Recurrent, Metastatic disease) in China due to scheduled pause (Parenteral) (NCT04139057)
  • 02 Jun 2023 Efficacy, safety and pharmacokinetics data from a phase I trial in Cervical-cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top